


This article was downloaded by:

On: 30 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Spectroscopy Letters

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597299>

Carbon-13 Chemical Shift Assignments for the Bisulfite Adducts of Uracil, 5-Deuterouracil, 5-Fluorouracil and 5-Chlorouracil

J. W. Triplett^a; G. A. Digenis^a; W. J. Layton^b; S. L. Smith^b

^a College of Pharmacy University of Kentucky, Lexington, Kentucky ^b Department of Chemistry, University of Kentucky, Lexington, Kentucky

To cite this Article Triplett, J. W. , Digenis, G. A. , Layton, W. J. and Smith, S. L.(1977) 'Carbon-13 Chemical Shift Assignments for the Bisulfite Adducts of Uracil, 5-Deuterouracil, 5-Fluorouracil and 5-Chlorouracil', *Spectroscopy Letters*, 10: 3, 141 — 147

To link to this Article: DOI: 10.1080/00387017708067505

URL: <http://dx.doi.org/10.1080/00387017708067505>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

CARBON-13 CHEMICAL SHIFT ASSIGNMENTS FOR THE
BISULFITE ADDUCTS OF URACIL, 5-DEUTEROURACIL,
5-FLUOROURACIL AND 5-CHLOROURACIL

Key words: uracil, bisulfite, 5-deuterouracil, 5-fluorouracil,
5-chlorouracil, carbon-13 NMR

J. W. Triplett*, G. A. Digenis*,

W. J. Layton⁺, and S. L. Smith⁺



*College of Pharmacy and +Department of Chemistry, University of
Kentucky, Lexington Kentucky 40506

ABSTRACT

Chemical shift assignments are made for the carbon atoms of the uracil-bisulfite adduct by use of specific labeling with deuterium and carbon-13. The signals of the analogous adducts from 5-chlorouracil and the pharmacologically important 5-fluorouracil are assigned.

Nucleophilic attack at C₆ is postulated as a key step in enzymatic reactions involving substitution at C₅ of biologically important pyrimidines, notably in the conversion of 2'-deoxyuridine-5'-monophosphate (5'-dUMP) to thymidine-5'-monophosphate

by thymidylate synthetase; the reaction which is blocked by anti-tumor agents such as 5-fluorouracil and 5-fluoro-2'-deoxyuridine (1). Reaction of bisulfite with uracil and its derivatives as shown in the first half of Scheme I is assumed to provide a valid model for these more complicated biological processes. Extensive study has shown these adducts²⁻⁶ to be intermediates in the exchange⁷ and dehalogenation⁸⁻¹⁵ reactions of substituted uracils as shown in the second half of Scheme I. Further, the fact that bisulfite is the aqueous form of the common pollutant sulfur dioxide gives these reactions intrinsic importance. For example, bisulfite has been shown to catalyze the deamination of cytosine to uracil⁴ and to inhibit ribosomal activity suggesting a possible mutagenic role for bisulfite¹⁶. Our interest



Scheme I

in using ^{13}C NMR to study the structure of complex intermediates and products from biological processes and to study the reaction of bisulfite with nucleic acids required unambiguous assignment of the ^{13}C chemical shifts of the simple bisulfite adducts of uracil and halouracils which we report here.

Uracil (U), 5-fluorouracil (5-FU), and 5-chlorouracil (5-ClU) were obtained from Aldrich Chemical Company and Calbiochem and used without further purification. 5-deuteroouracil (5-dU) was prepared by the method of Rork and Pitman⁶. Uracil enriched to 5% ^{13}C at position 6 was synthesised by methods reported elsewhere¹⁷. The spectra of these materials in d_6 -DMSO (they are practically insoluble in water) are reported in Table 1. The chemical shift assignments are consistent with those reported previously by a variety of investigators¹⁷ and are confirmed here by the expected couplings or intensity changes.

Reaction of uracil with bisulfite in water led to 5,6-dihydrouracil-6-sulfonate (U/HSO₃) whose ^{13}C NMR spectrum (Table 1) showed the disappearance of the signals at 100 and 141 ppm and the appearance of two new signals in the aliphatic region at 30.8 and 62.9 ppm. Off resonance decoupled or coupled spectra showed the upfield signal as a triplet and the downfield signal as a doublet establishing that the sulfonate group was attached to the carbon giving the downfield signal. When the adduct was formed from 5-deuteroouracil and HSO₃⁻, or from

Table 1
Carbon-13 Chemical Shifts^a

Compound	Solvent	C-2	C-4	C-5	C-6
Uracil	DMSO	151.3	164.1	100.8	141.8
5-dU	DMSO	151.5	164.6	100.2(t) ($J_{CD}=20.4\text{Hz}$)	142.1
6- ¹³ C-U	DMSO	151.7	164.7	100.5	142.4 (more intense)
5-FU	DMSO	149.6	157.4(d) ($J_{CF}=25.4\text{Hz}$)	139.3(d) ($J_{FC}=226.7\text{ Hz}$)	125.7(d) ($J_{CF}=31.3\text{Hz}$)
5-ClU	DMSO	150.2	159.6	105.6	139.2
U/HSO ₃ ⁻	H ₂ O	*b	*	30.8	63.0
5-dU/HSO ₃ ⁻	H ₂ O	*	*	30.8(t) ($J_{CD}=21\text{Hz}$)	63.8
6- ¹³ C-U/HSO ₃ ⁻	H ₂ O	*	*	30.9	63.0 (more intense)
5-FU/HSO ₃ ⁻	H ₂ O	161.4	174.5(d) ($J_{CF}=19.8\text{ Hz}$)	91.5(d) ($J_{CF}=187.6\text{ Hz}$)	68.4(d) ($J_{CF}=17.7\text{Hz}$)
5-ClU/HSO ₃ ⁻	H ₂ O	*	*	50.0	70.3

- a. Chemical shifts referenced to DMSO solvent or Dioxane in water as _____ and _____ respectively relative to TMS.
b. Signal too weak to detect.

uracil and DSO₃⁻ / D₂O, the same spectrum was observed with the signal at 30.8 ppm split into a triplet ($J_{CD} = 21\text{ Hz}$) confirming its assignment to C₅ of the adduct. The adduct formed from uracil enriched with ¹³C at carbon 6 shows the expected in-

crease in intensity for the signal at 63 ppm confirming its assignment to C₆ of the adduct.

The adducts of 5-ClU and 5-FU with bisulfite give analogous spectra reported in Table 1. The shifts for C₆ (70.3 ppm) and C₅ (49.97 ppm) in 5-ClU/HSO₃⁻ can be assigned by analogy with the uracil adduct shifts after allowing for the expected effect of the chlorine. It has been suggested that bisulfite addition at carbon-6 of 5-ClU results in the formation of an anionic species at carbon-5, stable enough to allow proton addition both cis and trans giving two isomers¹⁹. In this investigation only one bisulfite adduct of 5-ClU was observed. The large one-bond C₅-F coupling (187.6 Hz) and the smaller C₆-F coupling (17.7 Hz) permit the unambiguous assignment of C₅ (91.5 ppm) and C₆ (63.8 ppm) in the adduct from the antitumor agent 5-FU.

The fact that C-5 of uracil (ca. 100 ppm) and C-5 of its adduct (ca. 30 ppm) occur in regions of the ¹³C NMR spectrum which, for most biological samples of interest, do not contain other signals makes them particularly useful for the detection of the pyrimidine-bisulfite reaction in complex systems.

Spectra were measured with a Varian CFT-20 spectrometer. Typically, a 4K spectrum covering 200 ppm was accumulated using a pulse width of 7 microseconds (35° flip), no delay, an aquisition time of 0.512 seconds and broad band proton decoupling. Spectra from DMSO solutions required accumulation of a

few thousand scans. Spectra of the insoluble adducts in H₂O required 100,000 to 500,000 scans. Probe temperature was 30°C. The pH of all aqueous samples was 6.5-7.1.

References

1. P.V. Danenberg, R.J. Langenback, and C. Heidelberger, Biochemistry, **13**, 926 (1974).
2. R. Shapiro, R.E. Servis, and M. Welcher, J.A.C.S., **92**, 422 (1970).
3. H. Hayatsu, Y. Wataya, and K. Kai, J.A.C.S., **92**, 724 (1970).
4. H. Hayatsu, Y. Wataya, K. Kai, and S. Iida, Biochemistry, **9**, 2858 (1970).
5. Y. Wataya and H. Hayatsu, Biochemistry, **11**, 3583 (1972).
6. G.S. Rork and I.H. Pitman, J.A.C.S., **96**, 4654 (1974).
7. M.I. Smith Lomax and G.R. Greenberg, The Journal of Biological Chemistry, **242**, 1302 (1967).
8. F.A. Sedor, D.G. Jacobson, and E.G. Sander, J.A.C.S., **97**, 55 (1975).
9. E.G. Sander and C.L. Deyrup, Archives of Biochemistry and Biophysics, **150**, 600 (1972).
10. R.W. Erickson and E.G. Sander, J.A.C.S., **94**, 2086 (1972).
11. G.S. Rork and I.H. Pitman, J.A.C.S., **97**, 5566 (1975).
12. R. Shapiro, M. Welcher, V. Nelson, and V. DiFate, Biochimica et Biophysica Acta, **425**, 115 (1976).
13. R. Shapiro, M. Welcher, and V. DiFate, J.A.C.S., **96**, 906 (1974).
14. E.R. Garret, H.J. Nestler, and A. Somodi, J. Org. Chem., **33**, 3460 (1968).
15. G.S. Rork and I.H. Pitman, J. Pharm. Sci., **64**, 216 (1975).

16. V. Braverman, R. Shapiro, and W. Sver, Nucleic Acid Res. 2,
Sol (1975).
17. J.W. Triplett, G.A. Digenis, S. Mack and S.L. Smith,
J. Labelled Compounds, in press.
18. J.R. DeMember and F.A. Wallace, J.A.C.S., 97, 6240 (1975).
19. G.S. Rork and I.H. Pitman, J. Am.Chem.Soc., 97, 5559 (1975).

Received: 1-3-77

Accepted: 1-19-77